Ubs Group Ag Molecular Partners Ag Transaction History

Ubs Group Ag

  • $528 Billion
  • Q1 2025

A detailed history of Ubs Group Ag transactions in Molecular Partners Ag stock. As of the latest transaction made, Ubs Group Ag holds 6,351 shares of MOLN stock, worth $23,371. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,351
Previous 6,872 7.58%
Holding current value
$23,371
Previous $32,000 25.0%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 13, 2025
SELL
$3.76 - $5.81 $1,958 - $3,027
-521 Reduced 7.58%
6,351 $24,000
Q4 2024

Feb 14, 2025
BUY
$4.58 - $6.78 $7,447 - $11,024
1,626 Added 31.0%
6,872 $32,000
Q3 2024

Nov 14, 2024
BUY
$4.62 - $8.58 $8,246 - $15,315
1,785 Added 51.57%
5,246 $26,000
Q2 2024

Aug 13, 2024
BUY
$3.32 - $11.01 $10,408 - $34,516
3,135 Added 961.66%
3,461 $25,000
Q1 2024

May 13, 2024
BUY
$3.73 - $5.0 $1,215 - $1,630
326 New
326 $1,000
Q4 2022

Feb 08, 2023
BUY
$6.03 - $7.08 $17,836 - $20,942
2,958 New
2,958 $19,000
Q2 2022

Aug 10, 2022
SELL
$5.98 - $21.8 $3,653 - $13,319
-611 Closed
0 $0
Q1 2022

May 16, 2022
SELL
$16.51 - $31.89 $46,161 - $89,164
-2,796 Reduced 82.07%
611 $12,000
Q4 2021

Feb 14, 2022
BUY
$9.99 - $20.49 $34,035 - $69,809
3,407 New
3,407 $65,000
Q3 2021

Nov 15, 2021
SELL
$18.34 - $21.0 $421 - $483
-23 Closed
0 $0
Q2 2021

Aug 13, 2021
BUY
$19.25 - $21.01 $442 - $483
23 New
23 $0

Others Institutions Holding MOLN

# of Institutions
7
Shares Held
3.58M
Call Options Held
0
Put Options Held
0
View Full List

About MOLECULAR PARTNERS AG

MOLN Quotes by TradingView
  • Ticker MOLN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,514,000
  • Market Cap $120M
  • Description
  • Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, ...
More about MOLN
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email